Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Centre Hospitalier Universitaire Dijon
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06197425CT.gov Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer | — | Recruiting | — | — | — |
NCT07318805CT.gov A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT07407465CT.gov Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | — | Recruiting | — | — | — |
NCT06696768CT.gov Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06951503CT.gov AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06640166CT.gov Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. | — | Recruiting | — | — | — |
NCT05627635CT.gov FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05678257CT.gov A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | — | Terminated | — | — | — |
NCT05480306CT.gov Phase 2 Study of DKN-01 in Colorectal Cancer | — | Completed | — | — | — |
NCT05312398CT.gov CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen | — | Active Not Recruiting | — | — | — |
Show 14 more trialsShow fewer
NCT04731467CT.gov A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | — | Completed | — | — | — |
NCT04117945CT.gov Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT06031376CT.gov Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC | — | Completed | — | — | — |
NCT03366155CT.gov Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | — | Completed | — | — | — |
NCT03715933CT.gov Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | — | Recruiting | — | — | — |
NCT03376659CT.gov Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | — | Terminated | — | — | — |
NCT03368963CT.gov TAS102 in Combination With NAL-IRI in Advanced GI Cancers | — | Active Not Recruiting | — | — | — |
NCT02997228CT.gov Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | — | Active Not Recruiting | — | — | — |
NCT02758951CT.gov Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases | — | Active Not Recruiting | — | — | — |
NCT03050814CT.gov Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | — | Terminated | — | — | — |
NCT02413853CT.gov Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
NCT02292758CT.gov Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT01367275CT.gov Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | — | Terminated | — | — | — |
NCT00597506CT.gov Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | Centre Hospitalier Universitaire Dijon | P3 | B · 63 |
| Trifluridine | Centre Hospitalier Universitaire Dijon | P3 | BB |
| Regorafenib | City of Hope Medical Center | P2 | BB |
| Botensilimab | City of Hope Medical Center | P2 | BB |
| Balstilimab | City of Hope Medical Center | P2 | BB |
| Fluorouracilum | Centre Hospitalier Universitaire Dijon | P3 | BB |
| Cetuximab | Bayer | P2 | BB |
| Tipiracil | Academic and Community Cancer Research United | P2 | BB |
| Capecitabine | Gruppo Oncologico del Nord-Ovest | P3 | B |
+42 more in the Colorectal Adenocarcinoma cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Irinotecan in Colorectal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-colorectal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →